Literature DB >> 8710688

Effects of repeated boluses of sucrose on proliferation and on AOM-induced aberrant crypt foci in rat colon.

C Luceri1, G Caderni, L Lancioni, S Aiolli, P Dolara, V Mastrandrea, F Scardazza, G Morozzi.   

Abstract

Colonic mucosal proliferation, aberrant crypt foci (ACF) induction, and fecal bile acids, parameters connected to the risk of colon cancer development, were studied in female F344 rats treated with starch or sucrose boluses or with a sucrose diet. Cell proliferation was higher in animals treated with a single sucrose bolus than in those given a starch bolus (15 g/kg body wt), with 4.3 +/- 0.64 and 2.17 +/- 0.57 (SE) mitotic figures (MF) per crypt in the sucrose and starch bolus groups, respectively (p < 0.01). When azoxymethane (AOM, 20 mg/kg) was administered 24 hours after a single sucrose or starch bolus, the number of ACF per colon after 30 days was higher in the sucrose bolus group [107.5 +/- 9.5 (SE)] than in the starch bolus group (67.8 +/- 0.9, p < 0.01). In additional experiments, colon cell proliferation (MF/crypt) was higher in rats given boluses of sucrose three times per week for 40 days after AOM (20 mg/kg) [5.9 +/- 0.7 (SE)] than in rats given starch boluses (2.96 +/- 0.4) or fed sucrose continuously (3.6 +/- 0.5). On the contrary, after 40 days of dietary treatment, the number, dimension, and percentage of ACF secreting sulfomucins and sialomucins were not varied among these three groups. However, the percentage of "large ACF" (ACF with > or = 4 crypts) secreting sialomucins or predominantly sialomucins was higher (p < 0.05) in the sucrose bolus group than in the starch group. The concentration of fecal bile acids and long-chain fatty acids was the same in the sucrose and starch groups, but the concentrations of deoxycholic and oleic acid were significantly higher in the sucrose bolus group. In conclusion, the administration of sucrose as a bolus had a stronger effect than continuous sucrose feeding on some parameters related to colon carcinogenesis and might be considered a risk factor in colon carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710688     DOI: 10.1080/01635589609514441

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  7 in total

Review 1.  Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency.

Authors:  Denis E Corpet; Sylviane Taché
Journal:  Nutr Cancer       Date:  2002       Impact factor: 2.900

2.  Glycemic index and colorectal carcinogenesis.

Authors:  Edward Giovannucci
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

3.  Insulin injections promote the growth of aberrant crypt foci in the colon of rats.

Authors:  D E Corpet; C Jacquinet; G Peiffer; S Taché
Journal:  Nutr Cancer       Date:  1997       Impact factor: 2.900

4.  Serum fructosamine and colorectal adenomas.

Authors:  Giovanni Misciagna; Giampietro De Michele; Vito Guerra; Anna M Cisternino; Alfredo Di Leo; Jo L Freudenheim
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

5.  TGF-alpha expression as a potential biomarker of risk within the normal-appearing colorectal mucosa of patients with and without incident sporadic adenoma.

Authors:  Carrie R Daniel; Roberd M Bostick; William Dana Flanders; Qi Long; Veronika Fedirko; Eduard Sidelnikov; March E Seabrook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

6.  Evaluation of a 4-day repeated-dose micronucleus test in rat glandular stomach and colon using aneugens and non-genotoxic non-carcinogens.

Authors:  Emiko Okada; Yohei Fujiishi; Kazunori Narumi; Wakako Ohyama
Journal:  Genes Environ       Date:  2022-04-11

7.  Association between dietary sugar intake and colorectal adenoma among cancer screening examinees in Japan.

Authors:  Hourin Cho; Sanjeev Budhathoki; Rieko Kanehara; Atsushi Goto; Taiki Yamaji; Yasuo Kakugawa; Yutaka Saito; Takahisa Matsuda; Motoki Iwasaki; Shoichiro Tsugane
Journal:  Cancer Sci       Date:  2020-08-26       Impact factor: 6.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.